Myriad Genetics, Inc. (MYGN) has a negative trailing P/E of -1.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 136.4 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -84.79%, forward earnings yield 0.73%. PEG 1.32.
Criteria proven by this page:
Overall SharesGrow Score: 39/100 with 1/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2017 | 81.0 | -0.99 | 2.27 | 2.29 | - |
| 2018 | 19.8 | 0.04 | 2.69 | 3.36 | - |
| 2019 | 439.2 | -4.54 | 1.86 | 2.37 | - |
| 2020 | -4.2 | 0.00 | 0.77 | 1.32 | - |
| 2020 | -6.6 | -0.58 | 1.68 | 2.65 | - |
| 2021 | -78.9 | 0.89 | 2.22 | 3.11 | - |
| 2022 | -10.4 | -0.04 | 1.32 | 1.72 | - |
| 2023 | -6.0 | -0.05 | 2.02 | 2.10 | - |
| 2024 | -9.8 | 0.18 | 1.77 | 1.48 | - |
| 2025 | -1.6 | -0.01 | 1.56 | 0.70 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $0.32 | $771.4M | $21.8M | 2.8% |
| 2017 | $1.82 | $772.6M | $131M | 17% |
| 2018 | $0.06 | $851.1M | $4.6M | 0.5% |
| 2019 | $-2.69 | $638.6M | $-199.5M | -31.2% |
| 2020 | $-2.99 | $557M | $-223.7M | -40.2% |
| 2021 | $-0.35 | $690.6M | $-27.2M | -3.9% |
| 2022 | $-1.39 | $678.4M | $-112M | -16.5% |
| 2023 | $-3.18 | $753.2M | $-263.3M | -35% |
| 2024 | $-1.41 | $837.6M | $-127.3M | -15.2% |
| 2025 | $-3.96 | $824.5M | $-365.9M | -44.4% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $0.05 | $-0.05 – $0.20 | $863.75M | $861.77M – $866.29M | 7 |
| 2027 | $0.14 | $0.03 – $0.35 | $908.09M | $901.05M – $913.94M | 7 |
| 2028 | $0.24 | $0.20 – $0.28 | $956.75M | $952.8M – $960.69M | 2 |
| 2029 | $0.50 | $0.49 – $0.50 | $1B | $991.79M – $1.01B | 1 |
| 2030 | $0.66 | $0.65 – $0.67 | $1.04B | $1.03B – $1.05B | 1 |
